The Serbsky State Scientific Center for Social and Forensic Psychiatry is a psychiatric hospital and Russia's main center of forensic psychiatry. In the past, the institution was called the Serbsky Institute.

During the past decade, FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 19 clinical trials were completed, i.e. on average, 73.1% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 11 clinical trials were completed. i.e. 122.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF" #1 sponsor was "Pfizer" with 7 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "Boehringer Ingelheim" with 5 trials sponsored, "Amgen" with 4 trials sponsored and "AO GENERIUM" with 4 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF" #1 collaborator was "Novartis" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Innovative Therapies For Children with Cancer Consortium" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Gastroparesis" (3 trials), "Gaucher Disease, Type 1" (3 trials), "Colitis, Ulcerative" (2 trials) and "Dermatitis, Atopic" (2 trials). Many other conditions were trialed in "FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF" in a lesser frequency.

Most popular intervention types in "FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF" are "Drug" (32 trials), "Biological" (6 trials), "Other" (6 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Eliglustat tartrate" (3 trials), "Tirzepatide" (3 trials), "Tocilizumab" (3 trials) and "5-FU" (2 trials). Other intervention names were less common.

The vast majority of trials in "FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF" are 39 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF". undefined are not yet recruiting, 6 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 21 completed trials in FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF, 5 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".

FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF has several departments that took part in Clinical trials: "P.A. Herzen Oncological Inst. ; Oncology" - 51 trials, "Medical Radiological Research Center" - 32 trials, "Kursk Regional Oncologic Dispensary" - 5 trials, "Kursk Regional Oncology Centre" - 5 trials, "Institute of Urology of MoH" - 2 trials